---
title: "Apple's 200,000-person health AI study runs on OpenEvidence with no disclosed price"
description: "The 200,000-person study hands a $15 billion, ad-funded startup its first consumer channel, with no fee, equity or contract disclosed, and the closest public test of whether that free AI model is eating paid clinical reference lands in Wolters Kluwer's February results."
publisher: "The Inference"
section: "Health"
published: 2026-11-16T18:23:32.285Z
modified: 2026-11-16T18:23:32.285Z
canonical: https://theinference.org/article/apple-s-200-000-person-health-ai-study-runs-on-openevidence-with-no-disclosed-price
language: en
keywords: "Health, Apple, OpenEvidence, Medical AI, Wolters Kluwer"
---

# Apple's 200,000-person health AI study runs on OpenEvidence with no disclosed price

> The 200,000-person study hands a $15 billion, ad-funded startup its first consumer channel, with no fee, equity or contract disclosed, and the closest public test of whether that free AI model is eating paid clinical reference lands in Wolters Kluwer's February results.

## Two hundred thousand people, and no contract

On Sunday, November 15, 2026, at the HLTH conference in Las Vegas, [Apple](https://theinference.org/markets/companies/apple) and [OpenEvidence](https://theinference.org/markets/companies/openevidence) [launched the Apple Health AI Usage Study](https://www.apple.com/newsroom/2026/11/apple-launches-research-study-to-explore-the-use-of-ai-for-health/): a separate iPhone app where up to 200,000 US adults aged 21 and over ask everyday health questions of an AI built on OpenEvidence, then grade the answers on accuracy, detail and relevance [1][2]. OpenEvidence supplies the clinical engine, grounding responses in the New England Journal of Medicine, JAMA and Nature; Apple built the research experience [1][4].

Apple says nothing learned will train AI models, and OpenEvidence deletes queries and responses within 24 hours [4]. What has not been disclosed is anything commercial: no fee, no investment, no agreement between the two companies [3].

## OpenEvidence trades its engine for distribution

The silence is the news. OpenEvidence [raised $250 million at a $15 billion valuation](https://theinference.org/article/openevidence-raised-250-million-at-15-billion-pro-medicus-fell-48-in-a-year-on-the-same-doctor-screen) in late September, confirmed by CEO Daniel Nadler [5]. The model is free physician access funded by advertising; Sacra estimated a $300 million annualized revenue run rate as of end-July 2026, an estimate, not audited accounts [3].

A JAMA study published October 15, 2026, counted 952,008 verified US clinician users and 271 million questions from January 2024 to June 2026, with monthly active users climbing from 355 to 703,265 [3].

*Chart: **OpenEvidence already reaches three times the people Apple hopes to enroll** Bars comparing OpenEvidence's June 2026 monthly active clinician users (703,265), the physicians among its 952,008 verified users (556,200), and Apple's target of up to 200,000 study participants.*

*People, not dollars. The first bar is monthly active US clinicians in June 2026; the second is the physicians inside the 952,008 verified clinician users counted from January 2024 to June 2026 (JAMA study of October 15, 2026, as reported by Economie Matin); the third is Apple's stated enrollment ceiling for the study app, not a count of users. Sources: Economie Matin (3), Apple Newsroom (1). [3][1]*

Apple's endorsement puts a physician-focused tool in front of consumers, and Apple keeps the user relationship and the data. OpenEvidence, by the public record, is trading its clinical engine for distribution. Nadler's own framing at the launch: "Apple is the most trusted and loved brand and product among consumers... you have to bring these two things together" [2].

## The trust question cuts both ways

OpenEvidence's valuation rests on doctors' trust; consumer exposure either multiplies the audience or risks medicalizing a professional brand. [A March 2026 KFF survey](https://www.economiematin.fr/apple-openevidence-ia-medicale-marche-2026) found 32% of US adults had asked an AI chatbot about their health in the prior year, and 77% worried about medical data privacy [3]. The stakes of a wrong answer on the phone in someone's pocket are different from those at the point of care.

## February 24 is the scoreboard

The listed scoreboard is [Wolters Kluwer](https://theinference.org/markets/companies/wolters-kluwer), owner of UpToDate, the paid clinical reference OpenEvidence undercuts. Health grew 5% organically [in the nine months to September](https://markets.businessinsider.com/news/stocks/wolters-kluwer-2026-nine-month-trading-update-1036713229), with "continued good renewals" for UpToDate Enterprise [7].

Two days before Apple's launch, Wolters Kluwer [agreed to buy AgileMD for up to $100 million](https://hitconsultant.net/2026/11/13/wolters-kluwer-to-acquire-ai-clinical-decision-support-platform-agilemd/) to push UpToDate Expert AI, now in over 2,700 US hospitals, into EHR workflows [6]. [Its full-year results on February 24, 2027](https://startupfortune.com/apple-launches-a-study-app-with-openevidence-to-see-how-people-use-ai-for-health/), will show whether free AI citation engines are denting paid renewals [4]. Whether Apple ever ships a health chatbot in the Health app or Siri is undisclosed; the study results will be the tell [4].

Learn more in our earlier reporting on [the ACP licensing deal with OpenEvidence](https://theinference.org/article/acp-licenses-its-guidelines-to-openevidence-for-an-undisclosed-price) and in the sources below.

## Takeaway

Apple is giving OpenEvidence its first consumer channel for free, with no fee, equity or contract disclosed, and the nearest public read on whether free AI is eating paid clinical reference comes from Wolters Kluwer's February 24 results.

## Sources

1. [Apple Newsroom, Apple launches research study to explore the use of AI for health, 15 November 2026](https://www.apple.com/newsroom/2026/11/apple-launches-research-study-to-explore-the-use-of-ai-for-health/)
2. [STAT, Apple and OpenEvidence launch experimental health chat app experiment, 15 November 2026](https://www.statnews.com/2026/11/15/apple-openevidence-launch-health-chat-app-experiment-ai/)
3. [Economie Matin, Apple s'allie à OpenEvidence, l'IA médicale utilisée par 703 000 soignants en un mois, 16 November 2026](https://www.economiematin.fr/apple-openevidence-ia-medicale-marche-2026)
4. [Startup Fortune, Apple launches a study app with OpenEvidence to see how people use AI for health, 16 November 2026](https://startupfortune.com/apple-launches-a-study-app-with-openevidence-to-see-how-people-use-ai-for-health/)
5. [Forbes, OpenEvidence Confirms It Has Raised An Additional $250 Million At A $15 Billion Valuation, 30 September 2026](https://www.forbes.com/sites/saibala/2026/09/30/openevidence-confirms-it-has-raised-an-additional-250-million-at-a-15-billion-valuation/)
6. [HIT Consultant, Wolters Kluwer Acquires AgileMD for Up to $100M, 13 November 2026](https://hitconsultant.net/2026/11/13/wolters-kluwer-to-acquire-ai-clinical-decision-support-platform-agilemd/)
7. [Wolters Kluwer 2026 Nine-Month Trading Update, GlobeNewswire via Markets Insider, 4 November 2026](https://markets.businessinsider.com/news/stocks/wolters-kluwer-2026-nine-month-trading-update-1036713229)


---

Apple's 200,000-person health AI study runs on OpenEvidence with no disclosed price — The Inference. Canonical: https://theinference.org/article/apple-s-200-000-person-health-ai-study-runs-on-openevidence-with-no-disclosed-price
